KiOmed Pharma
De berekende faillissementskans van KiOmed Pharma over 12 maanden bedraagt 0,4% (zeer laag). Het bedrijf is actief sinds 2012 en het Belgisch Staatsblad bevat geen insolventie- of waarschuwingssignalen. Er zijn geen verwerkte jaarrekeningcijfers beschikbaar; deze conclusie steunt uitsluitend op register- en Staatsbladgegevens.
| Actief | 14 jaar |
| Bestuur | 12 |
| Vestigingen | 2 |
| Publicaties | 19 |
Statistische inschatting op basis van openbare bronnen, geen kredietadvies of vaststelling. Hoe berekenen we dit?
| Boekjaar | Type | Neerlegging | Referentie |
|---|---|---|---|
| 31-12-2025 | volledig | 02-06-2026 | 2026-00132153 |
| 31-12-2024 | volledig | 20-06-2025 | 2025-00163632 |
| 31-12-2023 | volledig | 05-06-2024 | 2024-00115460 |
| 31-12-2022 | volledig | 09-06-2023 | 2023-00116021 |
| 31-12-2021 | volledig | 22-06-2022 | 2022-20081190 |
| 31-12-2020 | volledig | 23-07-2021 | 2021-38500141 |
| 31-12-2019 | volledig | 10-07-2020 | 2020-30900243 |
| 31-12-2018 | volledig | 25-06-2019 | 2019-23300316 |
| 31-12-2017 | volledig | 20-06-2018 | 2018-21700448 |
| 31-12-2016 | volledig | 06-07-2017 | 2017-27900395 |
-
Clarentis SriBestuurderStaatsblad-akte 25121527 (25-09-2025)Actief25-09-2025 → heden
-
VALOISAdministrateur non statutaireStaatsblad-akte 25321883 (31-03-2025)Actief31-03-2025 → heden
-
SPARAXIS S.A.BestuurderStaatsblad-akte 24133616 (13-09-2024)Actief13-09-2024 → heden
-
Benoît FellinBestuurderStaatsblad-akte 23106635 (16-08-2023)Actief16-08-2023 → heden
-
Caroline ThielenBestuurderStaatsblad-akte 23106635 (16-08-2023)Actief16-08-2023 → heden
-
François BlondelPrésident exécutif du conseil d'administrationStaatsblad-akte 23106635 (16-08-2023)Actief16-08-2023 → heden
2 gebeurtenissen
- 16-08-2023 Benoemd· Président exécutif du conseil d'administration
- 30-05-2016 Ontslagen· Bestuurder
Toon 6 andere zittende bestuurders
-
Houtaï ChoumaneGedelegeerd bestuurderStaatsblad-akte 23106635 (16-08-2023)Actief16-08-2023 → heden
-
Marie HobeBestuurderStaatsblad-akte 23106635 (16-08-2023)Actief16-08-2023 → heden
-
Chagral Invest SRLRechtspersoonBestuurderStaatsblad-akte 25121527 (25-09-2025)Actief01-06-2023 → heden
2 gebeurtenissen
- 25-09-2025 Benoemd· Bestuurder
- 01-06-2023 Benoemd· Bestuurder
-
Samanda S.A.BestuurderStaatsblad-akte 23071547 (01-06-2023)Actief01-06-2023 → heden
-
Dr Pierre RigauxAdministrateur indépendantStaatsblad-akte 20118180 (09-10-2020)Actief09-10-2020 → heden
-
Marc NoletBestuurderStaatsblad-akte 23106635 (16-08-2023)Actief10-03-2020 → heden
3 gebeurtenissen
- 16-08-2023 Benoemd· Bestuurder
- 10-03-2020 Ontslagen· Bestuurder
- 10-03-2020 Benoemd· Bestuurder
Historisch, niet recent bevestigd (5)
-
Marc NOLET de BRAUWERE van STEELANDBestuurderStaatsblad-akte 16093242 (06-07-2016)Niet recent bevestigdlaatst bevestigd in akte van 2016
-
INNODE SARechtspersoonBestuurderStaatsblad-akte 16073900 (30-05-2016)Niet recent bevestigdlaatst bevestigd in akte van 2016
-
KiOmed PharmaCommisStaatsblad-akte 15176734 (18-12-2015)Niet recent bevestigdlaatst bevestigd in akte van 2015
-
Monsieur Philippe PireAuditorStaatsblad-akte 15176734 (18-12-2015)Niet recent bevestigdlaatst bevestigd in akte van 2015
-
S.C.R.L. ERNST & YOUNG REVISEURS D'ENTREPRISEAuditorStaatsblad-akte 15176734 (18-12-2015)Niet recent bevestigdlaatst bevestigd in akte van 2015
Vaste vertegenwoordigers (4)
-
Caroline ThielenReprésentant permanentStaatsblad-akte 24133616 (13-09-2024)Vaste vertegenwoordiger22-09-2021 → heden
2 gebeurtenissen
- 13-09-2024 Benoemd· Représentant permanent
- 22-09-2021 Benoemd· Representant permanent
-
Benoit FellinReprésentant permanentStaatsblad-akte 20037976 (10-03-2020)Vaste vertegenwoordiger10-03-2020 → heden
-
Françoise LeblancReprésentant permanentStaatsblad-akte 20037976 (10-03-2020)Vaste vertegenwoordiger- → 10-03-2020
-
Géry LefebvreRepresentant permanentStaatsblad-akte 21113286 (22-09-2021)Vaste vertegenwoordiger- → 22-09-2021
Voormalige bestuurders (3)
-
SPARAXISBestuurderStaatsblad-akte 25321883 (31-03-2025)Voormalig- → 31-03-2025
-
Flexximum R&D srlRechtspersoonBestuurderStaatsblad-akte 20118180 (09-10-2020)Voormalig- → 09-10-2020
-
Géry LEFEBVREBestuurderStaatsblad-akte 16093242 (06-07-2016)Voormalig06-07-2016 → heden
| Commissaris / bedrijfsrevisor | IBR/IRE-nummer | Periode |
|---|---|---|
| EYActief Commissaire aux comptes |
- | 22-09-2021 → heden |
Toon 3 eerdere commissarissen
| Ernst & Young Commissaire aux comptes opgevolgd door EY in 2021 |
- | 10-03-2020 → 22-09-2021 |
| EY Réviseurs d'Entreprises SRL Commissaire |
- | - → 13-09-2024 |
| Marie-Laure Moreau Commissaire opgevolgd door Ernst & Young in 2020 |
- | 25-08-2017 → 10-03-2020 |
| NACE primair | Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied(72109) |
| Rechtsvorm | NV(014) |
| Oprichtingsdatum | 04-06-2012 |
| Status | Actief |
| Postcode | 4041 |
Percelen gekoppeld aan dit bedrijf via zijn adressen in de KBO (zetel, vestigingen, bijkantoren), gekruist met het kadastraal percelenplan. Dit toont waar het bedrijf actief is, geen eigendomsregister.
| Perceel (capakey) | Regio | Oppervlakte | Gebouwen | Hoogte / verd. |
|---|---|---|---|---|
| 62042B0366/00B003 | Wallonië | 1,9 ha | - | - |
| 62071B0791/00G004 | Wallonië | 4.437 m² | 1 · 850 m² | 7,2 m · 2 verd. |
Eén tijdlijn van alles wat er met dit bedrijf is gebeurd, publicaties, insolventie- en levensloopgebeurtenissen, administratieve wijzigingen en neergelegde jaarrekeningen.
Wij kennen 23 Staatsblad-aktes van dit bedrijf. Daarvan is er nog geen enkele gelezen: wat erin staat, is hier niet vastgesteld en ook niet weerlegd.
25-09-2025 2 bestuurders benoemd
- Chagral Invest SRL, Bestuurder
- Clarentis Sri, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chagral Invest SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Clarentis Sri",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}31-03-2025 Kapitaalverhoging van €6.046.834,90 tot €14.726.836,31
- €8.680.001,41 → €14.726.836,31
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 14726836.31,
"delta_eur": 6046834.9,
"before_eur": 8680001.41,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KiOmed Pharma"
}
}16-01-2025 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-09-2024 2 bestuurders benoemd, 1 ontslagnemend
- SPARAXIS S.A., Bestuurder
- Caroline Thielen, Représentant permanent
- EY Réviseurs d'Entreprises SRL, Commissaire
Technische details
{
"events": [
{
"kind": "director_out",
"role": "commissaire",
"person": {
"rrn": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "SPARAXIS S.A.",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma DIVISION LIEGE"
}
}16-08-2023 6 bestuurders benoemd
- François Blondel, Président exécutif du conseil d'administration
- Houtaï Choumane, Gedelegeerd bestuurder
- Caroline Thielen, Bestuurder
- Benoît Fellin, Bestuurder
- Marc Nolet, Bestuurder
- Marie Hobe, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "Pr\u00E9sident ex\u00E9cutif du Conseil d\u0027administration",
"person": {
"rrn": null,
"name": "Fran\u00E7ois Blondel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Houta\u00EF Choumane",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Beno\u00EEt Fellin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marie Hobe",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}01-06-2023 2 bestuurders benoemd
- Chagral Invest Srl, Bestuurder
- Samanda S.A., Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chagral Invest Srl",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Samanda S.A.",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}03-01-2022 Publicatie in het Belgisch Staatsblad, Diversen
Technische details
{
"stage": null,
"notary": {
"name": "Ariane DENIS",
"firm_city": null,
"firm_name": "Yves Godin \u0026 Ariane Denis, Notaires Associ\u00E9s SRL",
"office_city": "Li\u00E8ge",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-01-03",
"filing_date": "2021-12-30",
"act_kind_objet": "CAPITAL, ACTIONS, DIVERS, STATUTS (TRADUCTION,"
},
"decision": {
"body": "bijzondere_algemene_vergadering",
"act_date": "2021-12-22",
"unanimous": null
},
"conversion": {
"effective_date": null,
"jurisdiction_to": "BE",
"legal_form_after": "Soci\u00E9t\u00E9 anonyme",
"jurisdiction_from": "BE",
"legal_form_before": "Soci\u00E9t\u00E9 anonyme"
},
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0846.318.862",
"name": "KIOMED PHARMA",
"role": "other",
"address": "Rue Haute Claire 4, 4041 Herstal",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"7:180",
"7:187",
"7:188",
"39, \u00A71"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La soci\u00E9t\u00E9 a divis\u00E9 ses actions existantes par cent, augmentant ainsi le nombre total d\u0027actions de 89.725 \u00E0 8.972.500. Elle a \u00E9galement \u00E9mis 635.000 nouveaux droits de souscription (\u00AB Warrants SOP 2021 \u00BB) pour financer une future augmentation de capital sous condition suspensive.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Ariane DENIS",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de KiOmed Pharma, tenue le 22 d\u00E9cembre 2021, a d\u00E9cid\u00E9 de diviser chaque action existante par cent, portant le capital \u00E0 8.972.500 actions sans valeur nominale. Elle a \u00E9galement \u00E9mis 635.000 droits de souscription (\u00AB Warrants SOP 2021 \u00BB) et a approuv\u00E9 une augmentation de capital conditionnelle \u00E0 l\u0027exercice de ces droits. Les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter ces changements, notamment en ajustant le montant du capital \u00E0 5.350.528,90 \u20AC.",
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal du 22 d\u00E9cembre 2021",
"les procurations et rapports sp\u00E9ciaux",
"la coordination des statuts"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "capital_shares"
}22-09-2021 2 bestuurders benoemd, 1 ontslagnemend
- Caroline Thielen, Representant permanent
- EY, Commissaire aux comptes
- Géry Lefebvre, Representant permanent
Technische details
{
"events": [
{
"kind": "director_in",
"role": "representant permanent",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "representant permanent",
"person": {
"rrn": null,
"name": "G\u00E9ry Lefebvre",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "EY",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}09-07-2021 Kapitaalverhoging van €174.000 tot €5.350.528,90
- €5.176.528,90 → €5.350.528,90
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5350528.9,
"delta_eur": 174000.0,
"before_eur": 5176528.9,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}09-10-2020 1 bestuurder benoemd, 1 ontslagnemend
- Dr Pierre Rigaux, Administrateur indépendant
- Flexximum R&D srl, Bestuurder
Technische details
{
"events": [
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Dr Pierre Rigaux",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Flexximum R\u0026D srl",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}10-03-2020 3 bestuurders benoemd, 2 ontslagnemend
- Marc Nolet, Bestuurder
- Benoit Fellin, Représentant permanent
- Ernst & Young, Commissaire aux comptes
- Marc Nolet, Bestuurder
- Françoise Leblanc, Représentant permanent
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Benoit Fellin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Fran\u00E7oise Leblanc",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}07-08-2019 Kapitaalverhoging van €985.422,07 tot €5.176.528,90
- €4.191.106,83 → €5.176.528,90
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5176528.9,
"delta_eur": 985422.0700000003,
"before_eur": 4191106.83,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}28-05-2019 Kapitaalvermindering van €4.313.637,52 tot €4.191.106,83
- €8.504.744,35 → €4.191.106,83
Technische details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 4191106.83,
"delta_eur": -4313637.52,
"before_eur": 8504744.35,
"contribution_type": null
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}20-05-2019 Kapitaalverhoging van €120 tot €8.504.744,35
- €8.504.624,35 → €8.504.744,35
- Inbreng in geld · Apport en numéraire
Technische details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 8504744.35,
"delta_eur": 120.0,
"before_eur": 8504624.35,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}10-12-2018 Verrichting in kapitaal of aandelen
Technische details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}25-08-2017 Marie-Laure Moreau benoemd tot commissaire
- Marie-Laure Moreau, Commissaire
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Marie-Laure Moreau",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOmed Pharma"
}
}06-07-2016 Statutenwijziging
Technische details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
},
"legal_form_change": {
"new": "soci\u00E9t\u00E9 anonyme",
"old": "soci\u00E9t\u00E9 anonyme",
"changed": false
}
}30-05-2016 1 bestuurder benoemd, 1 ontslagnemend
- INNODE SA, Bestuurder
- François BLONDEL, Bestuurder
Technische details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fran\u00E7ois BLONDEL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "INNODE SA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOmed Pharma"
}
}18-12-2015 3 bestuurders benoemd
- KiOmed Pharma, Commis
- S.C.R.L. ERNST & YOUNG REVISEURS D'ENTREPRISE, Auditor
- Monsieur Philippe Pire, Auditor
Technische details
{
"events": [
{
"kind": "director_in",
"role": "commis",
"person": {
"rrn": null,
"name": "KiOmed Pharma",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "S.C.R.L. ERNST \u0026 YOUNG REVISEURS D\u0027ENTREPRISE",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Monsieur Philippe Pire",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "SYNOLYNE PHARMA"
}
}| Officiële naamFR | KiOmed Pharma |